Valuation: the stock looks cheap on paper
After a rally since early October, Sanofi still changes hands at about 9 times projected earnings for the next year. That makes it the least expensive name among the world's 10 largest drugmakers by sales, compared with a peer average multiple near 17.3 based on analyst estimates.
Despite that low bar, the stock has lagged bigger rivals this year. Total return is 8.9% including dividends, trailing the Stoxx Europe 600 Health Care Index's 11%.
Dupixent is the engine - and the clock is ticking
Sales are booming for Dupixent, Sanofi's eczema and asthma therapy. But the medicine is expected to begin losing exclusivity in 2031, and many investors doubt Sanofi's experimental pipeline can fully replace that cash flow.
Some analysts think the market is leaning too hard into that worry. Intron Health's Naresh Chouhan this month upgraded his view from hold to buy; Bloomberg's tracking shows he set the most optimistic target price on the stock, implying a potential 41% rise from current levels. He expects Dupixent sales to climb from €15.7 billion last year to €34 billion in 2031. BNP Paribas's Peter Verdult also upgraded to outperform, arguing that worries about a thin pipeline are already baked into the valuation while near-term Dupixent earnings are being underestimated.
M&A talk, balance sheet room and the Insmed angle
One way to prepare for life after Dupixent is to buy growth. Sanofi is evaluating a takeover of US biotech Insmed, according to people familiar with the situation. Insmed, which is worth about $31.6 billion, sells two approved medicines for respiratory conditions. Both companies have declined to discuss any possible transaction.
When company outlooks shift, it's helpful to stay informed, so sign up for the free Market Briefs newsletter for concise daily context.
It would be the largest pharma deal since Pfizer's late-2023 purchase of Seagen Inc. for $43 billion. The news knocked Sanofi shares by 2.9% on Thursday, though they recouped part of that move Friday.
Jefferies analyst Michael Leuchten estimates Sanofi could deploy more than €25 billion, or $27.5 billion, without harming its dividend or credit rating, making a bid for Insmed plausible. In his words, "a sizeable M&A transaction should provide greater stability through the Dupixent patent cliff and, hence, create time for Sanofi to reload its pipeline." His takeaway: it looks big, but it is "doable, digestible and directionally" in line with management's aims.
Leadership, strategy and what it means for your portfolio
Chief Executive Officer Belén Garijo, who took the helm this year after a stint at Merck KGaA, is signaling the near- and long-term focus. "The whole organization is focused on managing Sanofi's post-Dupixent trajectory over the next decade," she said last month, adding, "Our priority is to protect earnings through Dupixent's loss of exclusivity."
Analysts are weighing her appetite for bold deals. Alphavalue's Abhishek Raval put it this way: "Bold moves rarely come without risks, and it might be the right time for Sanofi's management to take some calculated chances," noting that buying Insmed "would certainly be a massive step in answering the market's pressing question around Sanofi's life after Dupixent."
The bottom line: a bargain multiple, a cash-rich flagship drug, and a looming patent deadline. Add in upgrade momentum and real M&A capacity, and you get a stock where execution on pipeline and deals will likely drive whether that discount narrows into 2027 and beyond.
In uncertain industries, a clear daily briefing saves time, join Market Briefs to get five-minute explainers on markets, economy, crypto and real estate.
